Novo Nordisk's Answer to Retatrutide is Even Better: UBT251

Status
Not open for further replies.
New study on UBT251, which seems a little better for weight loss than reta, at 24 weeks out:

Novo, searching for a spark, spotlights new data for three-pronged obesity drug

Novo’s answer to a closely watched Lilly drug spurred roughly 20% weight loss after 24 weeks in a Phase 2 trial, results one of its executives claimed to be “differentiating.”

www.biopharmadive.com

quoted said:
An experimental, triple-acting obesity drug from Novo Nordisk helped some patients in a Phase 2 trial in China lose up to a fifth of their body weight , the company said Tuesday.

The study, run by Novo’s Guangdong, China-based development partner United Biotechnology, enrolled 205 patients who are overweight or have obesity and tested three different doses of the therapy, UBT251 , against a placebo over 24 weeks . According to Novo, the highest average weight loss observed over that time was 19.7% , versus 2% for placebo recipients.

Novo didn’t provide other details, but said all dose groups had statistically significant improvements compared to a placebo on key secondary measures of metabolic health. The most common side effects were gastrointestinal in nature and the “vast majority” were mild to moderate and diminished over time, the company said. Initial data from a global Phase 1b/2a study are expected next year...

In a mid-stage study published in The New England Journal of Medicine three years ago, retatrutide treatment led to as much as 17.5% weight loss after 24 weeks . Without mentioning retatrutide by name, Martin Holst Lange, Novo’s chief scientific officer and research head, claimed in a statement Tuesday that UBT251’s results suggest a “differentiated” clinical, safety and tolerability profile.
Click to expand...
 
I get nervous about how desperate it seems they're getting to have that 0.001% edge over each other. I'm glad tirz is working for me, because everything I know about corporations under pressure to make a billion dollars whispers that somebody's gonna push SOMETHING through that hurts people eventually. It's not tirz, and I doubt it's reta, but I believe it'll be SOMETHING, and it's so important to me not to be holding the early-adopter bag when that happens.
 
Better is a relative concept. Is losing more weight in a shorter amount of time always good? Gall and kidney stones are a possibility when losing large amounts of weight quickly. Also, if they achieved this by cranking up the glucagon agonist component, it could mean more thermogenesis and fat burning, but also potentially more tolerability issues. They haven't released the weights of GLP1/GIP and glucagon yet and Phase I readouts aren't scheduled until next year, but it will be interesting. They seem to be racing to find out what the limits of human metabolic weight loss really are.
 
The more new drugs the better. I think a lot of the drugs that have been in development that are injectable and not triple agonists will end up being dropped, as they won't compete with reta or any of the other ones being worked out. But over the longer term the more drugs the more competition and eventually saner pricing. The holy grail would be an oral triple agonist but I have not heard of one yet.

This one sounds very good, and unless something goes wrong, will keep going. You really need to know the incidence of side effects vs weight loss to compare drugs, as otherwise just giving a bit higher dose is going to make that drug look more effective, even if it causes more nausea or vomiting .
 
lessthanhalf said:
The more new drugs the better. I think a lot of the drugs that have been in development that are injectable and not triple agonists will end up being dropped, as they won't compete with reta or any of the other ones being worked out. But over the longer term the more drugs the more competition and eventually saner pricing. The holy grail would be an oral triple agonist but I have not heard of one yet.

This one sounds very good, and unless something goes wrong, will keep going. You really need to know the incidence of side effects vs weight loss to compare drugs, as otherwise just giving a bit higher dose is going to make that drug look more effective, even if it causes more nausea or vomiting .
Click to expand...
Yeah, saner prices in AUS maybe. The best one gets the golden ring in the USA.
 
Meh, high-dose mazdutide already largely matches retatrutide performance at 12 weeks. In fact, it's doing that in lower BMI people (believe mazdutide was an average starting BMI of ~32 and retatrutide was a starting BMI of ~37), making it all the more impressive. At 12 weeks the results are more about dosage and dose escalation rate for each.

I'm all for more good options in the space, but average weight loss numbers at the end of the trial will be what gets reported in the headlines.
 
And what even is that chart representing? The Y-axis appears to be in negative percent, but that's can't possibly be correct. Obviously none of these drugs are achieving the numbers plotted at the 12 week mark.
 
fatbegone said:
Couldn't find a graph in English. Apologies. Here's an article on UBT251 -> https://www.fiercebiotech.com/biote...triple-g-agonist-tied-15-weight-loss-12-weeks

View attachment 6479
Click to expand...
If we are whipping out who has the biggest weight loss drugs Why settle for nn-9559 or UBT-251 when you can look forward to NA-931

What NA-931 TargetsIt's a first-in-class, oral small-molecule quadruple agonist that simultaneously activates:

GLP-1 (appetite suppression, glucose control)

GIP (insulin sensitivity, fat metabolism)

Glucagon (energy expenditure, fat burning)

IGF-1 (insulin-like growth factor-1, which supports muscle growth , repair, and lean mass preservation)

The key differentiator here is the IGF-1 component—IGF-1 pathways help counteract the catabolic (muscle-breaking) effects common with GLP-1-based drugs, where 15–40% of weight loss can come from lean mass (especially concerning at age 52+ for sarcopenia risk).
 
lessthanhalf said:
Sadly it is not a peptide and as far as I know the chemical structure is not published so no pirate Chinese versions in the near future.
Click to expand...
I got to hand it to the Chinese, One things is they do have plenty of willing volunteers ( Uyghurs ) to preform these trials on the population.
 
DjJoshua said:
If we are whipping out who has the biggest weight loss drugs Why settle for nn-9559 or UBT-251 when you can look forward to NA-931

What NA-931 TargetsIt's a first-in-class, oral small-molecule quadruple agonist that simultaneously activates:

GLP-1 (appetite suppression, glucose control)

GIP (insulin sensitivity, fat metabolism)

Glucagon (energy expenditure, fat burning)

IGF-1 (insulin-like growth factor-1, which supports muscle growth , repair, and lean mass preservation)

The key differentiator here is the IGF-1 component—IGF-1 pathways help counteract the catabolic (muscle-breaking) effects common with GLP-1-based drugs, where 15–40% of weight loss can come from lean mass (especially concerning at age 52+ for sarcopenia risk).
Click to expand...
Big pharma finally catching up to bro science.
 
Calm Logic said:
Big pharma finally catching up to bro science.
Click to expand...
How about a 100% non glp1..... look at this.. The Allurion Gastric Balloon (also known as the Allurion Balloon or previously the Elipse Balloon in earlier studies). It's a swallowable intragastric balloon designed for non-surgical weight loss.
 
Status
Not open for further replies.

Trending content

Members online

No members online now.
Total: 1 (members: 0, guests: 1)

Forum statistics

Threads
2,620
Messages
55,146
Members
1
Latest member
Admin

Share this page

Back
Top